

# PROBLEM

INEFFICIENT CANCER DETECTION METHODS


COSTLY DIGITAL PATHOLOGY SCANNERS AND PATHOLOGIST DIAGNOSTICS

CANCER DIAGNOSTIC DISPARITIES

LOW-INCOME AREAS CANNOT AFFORD QUALITY CANCER DIAGNOSIS.

- Rare cancers and cancer adjacent diseases such as leiomyosarcoma, esophageal cancer, and Langerhans-cell histiocytosis **make up 25% of all cancers in the U.S.** (NIH)
- However, individually, rare cancers are defined as cancers that affect less than 40,000 people per year
- This makes it incredibly difficult for doctors to diagnose such cancers due to the lack of information and data needed to identify signs of a tumor
- This issue is **exacerbated further in low-income and rural areas** due to being exorbitantly expensive for some individuals, requiring highly trained doctors, and requiring costly equipment
- The **gold standard** for tumor diagnosis is tissue biopsy and analysis by a pathologist with a histopathology scanner
- However, the equipment and finances needed to fund a single scanner **can reach up to \$300,000** (Digital Pathology Association), making it incredibly difficult for developing areas to purchase and receive high-quality cancer diagnoses
- Patients may also have to individually **pay up to \$3000 for a full procedure** (Turquoise Health)

A cheaper and more accurate rare cancer detection system must be built



Makeup of all cancers as compared to selected cancers. Image Credit: Uddip Kashyap

# ENGINEERING GOALS

- Cost**: The device should be of a cost less than or equal to \$500
- Quality**: The device should be able to capture high-resolution images at different magnifications
- Viewing**: The device should have software that enables images to be stitched together for whole-slide image (WSI) viewing
- Usability**: A user-friendly application must be developed, and the software must be compatible with said application

# PathScan: A Digital Pathology Pipeline for Efficient Cancer Diagnostics

Uddip Kashyap

## METHODOLOGY: SCANNER

### 1 ProGAN Generation

- Upscale images from 4x4 pixels to 32x32 pixels
- Generate synthetic datasets of 100 images using **random noise vectors**

### 2 CNN and Fine-tuning

- Tune ProGAN hyperparameters to achieve **FID  $\leq 250$**
- Create CNN for detection of each rare cancer type


### 3 Scanner Design

- Design and develop scanner with **low-cost components**
- Capture and stitch images for analysis


### 4 Deployment and GUI

- Simple GUI with **AI integration** for cancer detection
- Data security mechanisms to protect patient information


### PRELIMINARY CAD RENDERING



### FINAL CAD MODELS




### PRIMARY PROTOTYPE



### SECONDARY PROTOTYPE






### SCAN RESULTS




## METHODOLOGY: AI

### Generator




Over time, the synthetic images progressively exhibit greater similarity to real images, capturing finer details and more accurate distributions of features


### Critic



# COST-BENEFIT ANALYSIS



## MANUFACTURING



Cost: \$122

Print Time: 30 hr

Assembly Time: 1 hr

## MARKETS

- Currently, the digital pathology market is expected to grow immensely to almost **\$2 billion** by 2030
- However, many potential sources for revenue and aid remain **untapped**, especially in rural regions
- A major cause of this is the cost of the digital pathology scanners themselves, which can cost upwards of **\$50,000** and have high maintenance costs
- PathScan, by contrast, costs just **\$122** to manufacture and can easily be sold for upwards of **\$500 without comprising its low cost**
- Additionally, AI-powered diagnostic software is becoming increasing prevalent in the digital pathology space, but almost all systems lack rare cancer diagnostic mechanisms
- PathScan currently stands as the **only effective rare-cancer diagnostic method** for histopathology, highlighting its potential for growth in the market

## REFERENCES

All images were created by the researcher, Uddip Kashyap

About Rare Cancers - NCI. (2019, February 27). <https://www.cancer.gov/pediatric-adult-rare-tumor/rare-tumors/about-rare-cancers>

Digital Pathology Market Size & Share Analysis Report, 2030. (n.d.). [www.grandviewresearch.com/industry-analysis/digital-pathology-systems-market](https://www.grandviewresearch.com/industry-analysis/digital-pathology-systems-market)

